GLP-1 Prescription Approval: Clinical Criteria & Biomarker Con...

Last reviewed: May 29, 2026

Last updated: May 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Getting approved for a GLP-1 prescription requires documented medical need, baseline health screening, and provider assessment of metabolic status and organ function. Most patients qualify if they have type 2 diabetes, obesity with comorbidities, or documented cardiovascular disease, supported by recent clinical guidelines emphasizing early intervention for metabolic disease.

The approval process involves more than meeting weight or A1C thresholds—it includes evaluating your full health picture: kidney function, thyroid status, medication interactions, and personal metabolic risk factors. PlexusDx supports this process by combining clinical assessment with genetic insights, helping you and your provider make evidence-based treatment decisions aligned with your unique metabolic profile.

Medical Eligibility Criteria for GLP-1 Treatment

Current guidelines recognize GLP-1 receptor agonists for type 2 diabetes management, weight management in obesity, and cardiovascular risk reduction. Eligibility typically requires documented diagnosis, baseline A1C or weight measurement, and absence of contraindications such as personal/family history of medullary thyroid carcinoma or MEN-2 syndrome.

Your provider will assess fasting glucose, HbA1c, kidney function (eGFR), and liver enzymes before approval. These baseline biomarkers establish treatment safety and help establish a meaningful comparison point for monitoring efficacy throughout your treatment course.

Key Clinical Assessments and Biomarkers Required for Approval

Before GLP-1 therapy begins, comprehensive metabolic screening identifies safety thresholds and establishes individualized treatment appropriateness. Several biomarkers directly influence approval timing and dosing strategy, ensuring you receive GLP-1 therapy safely.

Biomarker or Assessment	What It Measures	Typical Approval Threshold
HbA1c (if diabetic)	Average blood glucose over 3 months	Usually ≥5.7% or per provider discretion
Fasting Glucose	Blood sugar control baseline	≥100 mg/dL or type 2 diabetes diagnosis
Kidney Function (eGFR)	Glomerular filtration rate	eGFR ≥15 mL/min/1.73m²; dose adjustment if <30
Thyroid Function (TSH)	Screen for thyroid disease history	No active thyroid cancer; baseline TSH preferred
Liver Enzymes (ALT/AST)	Hepatic function and safety	No acute liver disease; mild elevation usually safe
Body Mass Index (BMI)	Weight classification for obesity indication	≥27 kg/m² with comorbidities or ≥30 kg/m²

Cardiovascular and Renal Risk Assessment in Approval Decision-Making

GLP-1 medications offer cardiovascular benefits documented in major trials, but kidney function significantly influences dosing and monitoring frequency. Providers evaluate eGFR, proteinuria, and blood pressure to confirm GLP-1 safety and determine whether dose escalation requires adjusted intervals.

Patients with established cardiovascular disease, heart failure, or moderate-to-severe kidney impairment may qualify for GLP-1 therapy, but approval often includes more frequent monitoring and potentially slower dose escalation protocols. Your provider will discuss these considerations during consultation.

How Genetic Factors Support Personalized Approval and Treatment Planning

While genetic variants do not determine GLP-1 approval directly, predispositions in peptide-signaling pathways can inform your provider's risk-benefit analysis and help identify whether GLP-1 aligns with your metabolic biology. Common variants in GLP1R, GIPR, FTO, and MC4R genes reflect individual variation in appetite regulation and metabolic response patterns.

PlexusDx's Precision Peptide Genetic Test reveals genetic predispositions in these peptide pathways, providing context for how your body may respond to GLP-1 therapy. This information supports more targeted conversations with your provider about treatment fit, dose initiation strategy, and monitoring expectations—helping move approval discussions from general criteria to your individual profile.

Provider Consultation Framework: Questions to Ask Before Approval

Effective approval conversations include discussing your metabolic history, family risk factors, current medications, and personal treatment goals. Ask your provider whether your baseline biomarkers support immediate initiation, whether dosing adjustments suit your kidney function, and what monitoring schedule to expect.

Bring recent lab work, a complete medication list, and information about any previous weight-loss medication experiences. If you've completed a genetic test showing peptide pathway predispositions, sharing those insights can deepen your provider's understanding of your metabolic risk profile and support a more personalized treatment plan.

Safety Considerations and Contraindications That Affect Approval Status

Absolute contraindications include personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, severe kidney disease (eGFR <15), and recent acute pancreatitis. Relative contraindications—such as diabetic retinopathy, moderate kidney disease, or recent surgery—require modified dosing or closer monitoring rather than disqualifying you entirely.

If you have a history of gastroparesis, severe gastrointestinal disease, or inflammatory bowel conditions, your provider may still approve GLP-1 therapy but with cautious dose escalation and symptom monitoring. Transparent communication about your full medical history ensures your provider can approve treatment safely and design a monitoring plan that protects your health.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions in key peptide-signaling genes (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that relate to appetite regulation and metabolic response. This genetic context may help provide additional framework for your provider's approval decision by identifying whether your genetic profile aligns with GLP-1 mechanism of action and expected response patterns.

The genetic test does not predict exact medication response or guarantee treatment success—genetics represents one layer of biological complexity. Instead, it can support a more informed conversation about treatment fit, baseline expectations, and monitoring strategy. When combined with clinical biomarkers (kidney function, glucose control, cardiovascular status), genetic insights help create a fuller picture of your individual metabolic profile.

As you pursue GLP-1 approval, sharing your Precision Peptide Genetic Test results with your provider can enhance the discussion about personalized treatment initiation, dose progression, and side effect management. This integrated approach—blending clinical assessment, biomarker data, and genetic context—transforms the approval process from a checklist into a precision-wellness conversation tailored to your unique biology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.